-
51.发明申请公开(公告)号：US20210353731A1
公开(公告)日：2021-11-18
申请号：US17163932
申请日：2021-02-01
IPC分类号： A61K39/015 , C07K14/445 , C12N1/36
摘要： The disclosure relates to doubly attenuated malaria parasites that have had the functionality of LISP2 and PlasMei2 genes interrupted through genetic manipulation. The double attenuated malaria parasites disclosed herein are useful for methods and compositions for stimulating of vertebrate host immune systems because of the complete cessation of lifecycle progression in the late liver stage, while providing a comprehensive antigenic presentation representing wildtype liver stage parasites. The disclosure also relates to the additional blood stage and gametocyte antigens to compositions of genetically attenuated malaria parasites (GAPs) to enhance efficient immune stimulation and prevention of disease and transmission related to the presence of blood stage parasites.
-
公开(公告)号：US20210340573A1
公开(公告)日：2021-11-04
申请号：US17049782
申请日：2019-04-25
发明人： Andrew M. Scharenberg , David J. Rawlings , Karen Sommer , Samuel West , Yuchi Chiang Honaker , Ryo Takeuchi
IPC分类号： C12N15/90 , C12N15/113 , C12N15/86 , C07K14/715
摘要： The present application relates to, inter alia, compositions including proteins for expression in host cells to render them resistant to rapamycin. The application further relates to methods of using the proteins, cells, and compositions disclosed therein for modulating cell signaling and for selective expansion of cells.
-
公开(公告)号：US20210283233A1
公开(公告)日：2021-09-16
申请号：US17178111
申请日：2021-02-17
发明人： Jonathan Kurtis , Christian Parcher Nixon , Dipak Kumar Raj , Jennifer Frances Friedman , Michal Fried , Patrick Emmet Duffy
IPC分类号： A61K39/015 , C07K14/445 , A61K39/395 , C07K16/44 , C07K16/20
摘要： The invention provides compositions and methods for preventing or reducing the severity of malaria.
-
公开(公告)号：US20210269772A1
公开(公告)日：2021-09-02
申请号：US17260111
申请日：2019-07-16
申请人： UNIVERSITY OF WASHINGTON , SEATTLE CHILDREN'S HOSPITAL DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE
发明人： Suzie H. PUN , Michael JENSEN , Nataly KACHEROVSKY , Ian CARDLE
IPC分类号： C12N5/0783 , C12N13/00 , C12N15/115 , A61K35/17 , C12N15/10
摘要： Described herein is a reversible aptamer selection technology for production-scale isolation of label-free cells (e.g., CD8+ T cells). Provided herein are methods for isolating a cell of interest from a biological sample by contacting the biological sample with an aptamer that specifically binds a cell surface marker specific for the cell of interest; separating the aptamer-bound cells from cells not bound to the aptamer; and recovering a cell of interest by disrupting binding of the aptamer to the cell surface marker.
-
55.发明申请公开(公告)号：US20200248260A1
公开(公告)日：2020-08-06
申请号：US16640323
申请日：2018-08-20
发明人： Michael Portman
IPC分类号： C12Q1/6883
摘要： Some embodiments of the methods and compositions provided herein relate to the detection of biomarkers for Kawasaki disease (KD), the diagnosis of KD in a subject, and/or the amelioration or treatment of KD in a subject. In some embodiments, a biomarker can include a long intergenic non-coding RNA (lincRNA). In some embodiments, the biomarker can be present in an exosome-enriched serum sample from a subject.
-
公开(公告)号：US20200078405A1
公开(公告)日：2020-03-12
申请号：US16657666
申请日：2019-10-18
申请人： Fred Hutchinson Cancer Research Center , Seattle Children's Hospital, dba Seattle Children's Research Institute
IPC分类号： A61K35/17 , C07K16/40 , C07K16/32 , C07K16/28 , C07K14/715 , C07K14/705 , C07K14/725
摘要： The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
-
公开(公告)号：US20190255109A1
公开(公告)日：2019-08-22
申请号：US16253562
申请日：2019-01-22
申请人： ENDOCYTE, INC. , PURDUE RESEARCH FOUNDATION , SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE)
发明人： Philip Stewart LOW , Haiyan CHU , Yingjuan June LU , Christopher Paul LEAMON , Leroy W. WHEELER, II , Michael C. JENSEN , James MATTHAEI
IPC分类号： A61K35/17 , A61P35/00 , A61K31/519 , A61K31/365 , A61K9/00 , A61K38/17
摘要： The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells wherein the CAR T cells comprise a CAR and the CAR comprises an E2 anti-fluorescein antibody fragment, and administering to the patient a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.
-
公开(公告)号：US20180327781A1
公开(公告)日：2018-11-15
申请号：US15773927
申请日：2016-11-08
IPC分类号： C12N15/86 , C12N15/113
CPC分类号： C12N15/86 , A61K31/7088 , C07K14/005 , C07K14/16 , C07K14/1825 , C12N9/22 , C12N15/1131 , C12N15/87 , C12N2310/20 , C12N2730/10141
摘要： The present application generally compositions comprising a synthetic delivery RNA comprising a first sequence from a viral genome and/or a second sequence from a viral genome and wherein the synthetic delivery RNA further comprises a nucleic acid sequence encoding a gene. The application further relates to methods of using the composition for delivering a nucleic acid to a nucleus of a cell disclosed herein. The application further relates to methods of treating, inhibiting, or ameliorating a disease in a subject including administering to the subject a cell disclosed herein.
-
公开(公告)号：US20180282692A1
公开(公告)日：2018-10-04
申请号：US15921353
申请日：2018-03-14
发明人： David J. Rawlings , Richard James , Shaun W. Jackson , Iram Khan , King Hung
摘要： The present application relates to plasma cells and plasma cell precursors that express a macromolecule, such as a protein, protein mimetic or a peptide and compositions comprising these plasma cells or plasma cell precursors. The application further relates to methods of using and making the plasma cells and plasma cell precursors that express the macromolecule. Methods of treatment comprising administering the plasma cells or plasma cell precursors are also contemplated.
-
60.发明申请公开(公告)号：US20180272007A1
公开(公告)日：2018-09-27
申请号：US15950562
申请日：2018-04-11
CPC分类号： A61K48/0066 , A61K41/0047 , C12N15/63 , C12N15/67 , C12N2710/10343 , C12N2750/14143 , C12P19/34
摘要： Disclosed herein are polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, methods of engineering the polynucleotides having a plurality of thymine nucleotides and an endonuclease recognition site inserted therein, and methods of enhancing transcription, translation, and increasing stability of a polynucleotide.
-
-
-
-
-
-
-
-
-
搜索结果
112 条记录 (耗时 0.066 秒)
